Platinum Investment Management Ltd. Invests $1.86 Million in Boston Scientific Corporation $BSX

Platinum Investment Management Ltd. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,554 shares of the medical equipment provider’s stock, valued at approximately $1,864,000.

A number of other institutional investors have also modified their holdings of BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC increased its position in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its position in shares of Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after acquiring an additional 2,556 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Stock Performance

Shares of BSX stock opened at $46.83 on Friday. The company’s 50 day moving average is $56.37 and its 200 day moving average is $74.95. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52-week low of $45.99 and a 52-week high of $109.50. The firm has a market cap of $69.60 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

BSX has been the topic of a number of research reports. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Piper Sandler reissued an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday. Leerink Partners cut their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Barclays cut their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.